In Vivo is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

Brought to you by

mRNA therapeutics biotech Moderna raises $474mm in Series F preferred stock financing

Executive Summary

Moderna Therapeutics Inc. (mRNA therapeutics) raised $474mm in a preferred stock equity financing of 54mm Series F shares at $8.78 from new and existing institutional investors, and strategic pharmaceutical partners in the US, Europe and Asia, including AstraZeneca and Boston Biotech Ventures. The company will use the proceeds for its clinical and preclinical pipeline, for construction of a new manufacturing facility, for sustained investment in its mRNA platform (at pace of $100mm per annum), and for continued expansion into new therapy areas and modalities. The company also just closed on its first BARDA grant for $125mm to advance its Zika mRNA vaccine and now has over $1.4bn in cash on its balance sheet at its disposal.
Deal Industry
  • Pharmaceuticals
  • Pharmaceuticals
    • Vaccines
    • Drug Delivery
      • Pulmonary
  • Biotechnology
    • Antisense, Oligonucleotides
    • Large Molecule
    • Drug Discovery Tools
      • Genomics-Proteomics
Deal Status
  • Final
Deal Type
  • Financing
    • Private Placement

Related Companies